Pharmacoeconomic review report. indication : the topical treatment of impetigo in patients aged two months and older. Ozenoxacin 1% cream (Ozanex), (Ferrer internacional, S.A.) :
Ozenoxacin 1% cream is a topical non-fluorinated quinolone antibiotic indicated for the treatment of impetigo in patients aged two months or older. The recommended use for ozenoxacin is the application of a thin layer of cream to affected areas twice daily for five days. It is available in 10 g tube...
Saved in:
| Online Access: |
Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | p2596145 | ||
| 005 | 20240206154734.0 | ||
| 006 | m o d | ||
| 007 | cr cn |||||||| | ||
| 008 | 190502s2018 onc ob 000 0 eng | ||
| 035 | |a (DNLM)BKSHLF:NBK539347 | ||
| 035 | |a 1747205 | ||
| 040 | |a DNLM |b eng |e rda |c DNLM |d UtOrBLW | ||
| 042 | |a pcc | ||
| 043 | |a n-cn--- | ||
| 060 | 0 | 0 | |a WR 225 |
| 245 | 0 | 0 | |a Pharmacoeconomic review report. |p Ozenoxacin 1% cream (Ozanex), (Ferrer internacional, S.A.) : |b indication : the topical treatment of impetigo in patients aged two months and older. |
| 246 | 1 | |a Ozenoxacin 1% cream (Ozanex), (Ferrer internacional, S.A.) | |
| 246 | 1 | |a Pharmacoeconomic review report for ozenoxacin (Ozanex) | |
| 264 | 1 | |a Ottawa (ON) : |b Canadian Agency for Drugs and Technologies in Health, |c October 2018. | |
| 300 | |a 1 online resource (1 PDF file (23 pages)). | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a CADTH common drug review | |
| 500 | |a "Version: Final." | ||
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a Ozenoxacin 1% cream is a topical non-fluorinated quinolone antibiotic indicated for the treatment of impetigo in patients aged two months or older. The recommended use for ozenoxacin is the application of a thin layer of cream to affected areas twice daily for five days. It is available in 10 g tubes at $17.78 per tube, or $1.78 per gram. The manufacturer submitted a cost-utility analysis with a 14-day time horizon -- conducted from a Canadian public health care payer perspective -- which compared ozenoxacin to fusidic acid and mupirocin (the two topical antibiotics available in Canada). The submitted model was in the form of a decision tree with patients receiving a topical antibiotic treatment and subsequently experiencing cure or no cure based on treatment efficacy. An indirect treatment comparison was used to compare the treatment efficacy of ozenoxacin to fusidic acid, while a Cochrane systematic review and CADTH Rapid Response were used to support the assumption of equal efficacy between fusidic acid and mupirocin. The manufacturer reported that ozenoxacin is less costly and is associated with greater quality-adjusted life-years (QALYs) (dominant) compared with fusidic acid, and the incremental cost-utility ratio (ICUR) compared with mupirocin was $55,792 per QALY. | |
| 536 | |a Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. | ||
| 588 | |a Description based on online resource; title from PDF title page (viewed June 10, 2019). | ||
| 650 | 1 | 2 | |a Impetigo |x drug therapy. |0 D007169Q000188 |
| 650 | 1 | 2 | |a Infant. |0 D007223 |
| 650 | 2 | 2 | |a Child. |0 D002648 |
| 650 | 2 | 2 | |a Quinolones |x therapeutic use. |0 D015363Q000627 |
| 650 | 2 | 2 | |a Quinolones |x economics. |0 D015363Q000191 |
| 650 | 2 | 2 | |a Cost-Benefit Analysis. |0 D003362 |
| 650 | 7 | |a Children. |2 homoit |0 homoit0000255 | |
| 650 | 7 | |a Family members. |2 homoit |0 homoit0000421 | |
| 651 | 2 | |a Canada. |0 D002170 | |
| 655 | 2 | |a Tables. |0 D020501 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e issuing body. |0 n 2007182676 | |
| 830 | 0 | |a Common drug review clinical review report. |0 n 2014186107 | |
| 951 | |a 2596145 | ||
| 998 | |a BKSHLF |b 20190502 | ||
| 999 | f | f | |i c0d68b5b-5da5-5e4e-ac65-329ded56c142 |s 5f7338f7-2a33-5030-8006-8df0dbf83015 |t 0 |
| 952 | f | f | |a Massachusetts College of Pharmacy and Health Sciences |b Online |c Online |d E-Collections |t 0 |e NCBI |h Other scheme |
| 856 | 4 | 0 | |t 0 |u http://www.ncbi.nlm.nih.gov/books/NBK539347/ |y Full text |
